17,261 trials
Non-small Cell Lung Cancer Metastatic · Targetable Oncogenes (EGFR, ALK, ROS1)
Primary: 1-year Frequency of Distant Failures (DF) After Stereotactic Body Radiation Therapy (SBRT) — 19 percentage of participants
Kawasaki Disease
Primary: Number of Participants With Adverse Events — 2; 3; 13 participants
Drug and/or Toxin-induced Diarrhea
Primary: Proportion of Patients Experiencing a Maximum Grade ≥ 2 Diarrhea During the First Cycle of Chemotherapy in the Target Population — 2.5; 5.0; 5.8; 9.8 percentage of…
Anemia
Primary: Observed Maximum Concentration (Cmax) — 1.022; 2.40; 3.66; 3.97 ug/mL
Glycogen Storage Disease Type II Pompe Disease
Primary: Number of Participants With Treatment-Emergent Adverse Events (TEAEs), Treatment-Emergent Serious Adverse Events (TESAEs), Infusion Associated Reactions (IARs) and…
NASH - Nonalcoholic Steatohepatitis
Primary: Percentage of Change From Baseline in Liver Fat Content as Assessed by MRI-PDFF — -26.8; -35.6; -33.0; 5.4 percentage of change
COVID-19
Primary: Percentage of Participants With Seroresponse to the Spike (S) Antigen of AZD1222 as Measured by Meso Scale Discovery (MSD) Serology Assay — 100.0; 0.0; 100.0; 0.0…
Essential Tremor
Primary: Part A: Change From Baseline in Essential Tremor Rating Assessment Scale (TETRAS) Upper Limb Score — -1.427; -2.912 Scores on a scale — p=0.1048
Atopic Dermatitis
Primary: Number of Participants With Treatment Emergent Adverse Events (TEAEs) and Treatment Emergent Serious Adverse Events (TESAEs) — 7; 12; 0; 0 Participants
Urinary Retention Postoperative
Primary: Time to Spontaneous Void — 1.63; 1.42 hours
Cognitive Dysfunction · Covid19
Primary: Change in Cognitive Function, as Measured by Number Correct on the Digit Symbol Matching Task — 63.0; 63.5; 67.8; 69.0 number of correct matches — p=0.54
Autism Spectrum Disorder
Primary: Change in the Autism Behavior Inventory, Short Form (ABI-S) — -2.9; -0.8 score on a scale — p=<0.05
SARS-CoV-2 · Influenza
Primary: Number of Participants With Solicited Local and Systemic Adverse Reaction (ARs) — 38; 80; 90; 92 Participants
Kidney Transplant Rejection
Primary: Maximum Reduction in Donor Specific Antibodies (DSA) Level During the 5 Days Following the Start of Treatment — 94; 36 percentage of maximum DSA reduction
Eosinophilic Gastritis · Eosinophilic Gastroenteritis · Eosinophilic Duodenitis
Primary: The Safety and Tolerability of AK002 by Evaluating Adverse Events Assessed Using the CTCAE Version 4.03 — 21; 35; 15; 22 Participants